Filing Analysis
📄 Other SEC Filing
Filed Jun 09, 2026
⚪ LOW
Verrica Pharmaceuticals reported the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. Stockholders approved the election of directors, executive compensation, the ratification of KPMG LLP as auditors, and the Amended and Restated 2018 Equity Incentive Plan.
📋 Key Facts
- Annual Meeting held on June 5, 2026, with 81.89% of outstanding shares (14,069,331 shares) represented.
- Paul B. Manning and Lawrence Eichenfield were elected as directors until 2029.
- The Amended and Restated 2018 Equity Incentive Plan was approved (11,142,881 votes For vs 433,852 Against).
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation was approved on an advisory basis.
📢 Regulation FD Disclosure
Filed May 12, 2026
⚪ LOW
Verrica Pharmaceuticals Inc. reported its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
🚩 Red Flags
- The company is currently operating with an Interim Chief Financial Officer (John J. Kirby), which can indicate a period of management transition.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 12, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
- The report was signed by John J. Kirby in his capacity as Interim Chief Financial Officer.
📄 Other SEC Filing
Filed Mar 11, 2026
⚪ LOW
Verrica Pharmaceuticals Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The announcement was made via a press release furnished as Exhibit 99.1.
🚩 Red Flags
- The company is currently led by an Interim CFO, which may indicate executive turnover.
📋 Key Facts
- Announced Q4 and full-year 2025 results on March 11, 2026.
- Filing includes Item 2.02 for Results of Operations and Financial Condition.
- The report was signed by John J. Kirby, Interim Chief Financial Officer.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.